Dermata Therapeutics, Inc. (DRMA): Total Assets
$7.86M
As of 2025-12-31
$5.32M
As of 2026-06-30
+4.2%
3-year compound annual growth
+67.0%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $7.86M | +122.5% | 2026-03-26, Balance as of period end |
| 2024-12-31 | $3.53M | -55.7% | 2026-03-26, Balance as of period end |
| 2023-12-31 | $7.98M | +14.9% | 2025-03-17, Balance as of period end |
| 2022-12-31 | $6.94M | -40.3% | 2024-03-21, Balance as of period end |
| 2021-12-31 | $11.62M | n/m | 2023-02-21, Balance as of period end |
| 2020-12-31 | $605.5K | n/a | 2022-03-28, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Dermata Therapeutics, Inc. (DRMA) | 2025-12-31 | $7.86M | +122.5% |
| Processa Pharmaceuticals, Inc. (PCSA) | 2025-12-31 | $7.81M | +142.0% |
| Acurx Pharmaceuticals, Inc. (ACXP) | 2025-12-31 | $7.69M | +99.3% |
| GT Biopharma, Inc. (GTBP) | 2025-12-31 | $8.11M | n/a |
| Silo Pharma, Inc. (SILO) | 2025-12-31 | $7.61M | +2.6% |
| Rocket One Inc. (RKTO) | 2025-12-31 | $7.60M | -1.4% |
| Oncolytics Biotech Inc (ONCY) | 2025-12-31 | $7.58M | -43.5% |
| Revium Rx. (RVRC) | 2025-12-31 | $8.30M | -59.1% |
| Ensysce Biosciences, Inc. (ENSC) | 2025-12-31 | $7.45M | +33.1% |
Compare DRMA, PCSA, ACXP, GTBP side by side · Screen every company in Pharmaceutical Preparations ↗